<DOC>
	<DOCNO>NCT00955786</DOCNO>
	<brief_summary>This phase 1 study CX-3543 design test safety , tolerability high safe dose level drug patient advance solid tumor cancer .</brief_summary>
	<brief_title>Dose-escalation Study CX-3543 Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>CX-4945 first-in-class small-molecule target cancer therapeutic derive validated fluoroquinolone class drug . This drug rationally design target G-quadruplex ( QPLX ) DNA structure disrupt protein-DNA interaction essential cancer cell . The QPLX target quarfloxin form within ribosomal DNA ( rDNA ) QPLX bound nucleolin protein.This Phase 1 study CX-3543 design test safety , tolerability high safe dose level drug patient advance solid tumor cancer .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients histologically confirm solid tumor lymphomas . Tumor progression receive standard/approved chemotherapy approve therapy . One tumor measurable radiograph CT scan , evaluable disease . ( e.g. , malignant ascites ) Karnofsky performance status great equal 70 . Life expectancy least 3 month . Age least 18 year . Patients must central IV access , agree insertion central IV line . A negative urine pregnancy test ( female . ) Acceptable liver function evaluate laboratory result Acceptable hematologic status evaluate laboratory result No clinically significant urinalysis abnormality Acceptable coagulation status evaluate laboratory result Fertile men woman must use effective contraceptive method study . Seizure disorder control anticonvulsant therapy . Known brain metastasis ( unless previously treat well controlled period great equal 3 month . ) Severe chronic obstructive pulmonary disease hypoxemia pulmonary compromise correctable therapy . Major surgery , diagnostic surgery , within 4 week prior first dose test drug . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . Pregnant nursing woman . Treatment radiation therapy , surgery , chemotherapy , investigational therapy within 4 week prior study entry ( 6 week nitrosoureas Mitomycin C. ) Unwillingness inability comply procedure require protocol . Known infection HIV , hepatitis B , hepatitis C. Clinically significant bleeding event within last 3 month , unrelated trauma , underlying condition would expect result bleed diathesis . Patients currently receive investigational therapy . Patients exhibit allergic reaction similar structural compound ( e.g. , fluoroquinolones ) , biological agent , formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>G-Quadruplex</keyword>
</DOC>